1/4/2012
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007
5/3/2011
Rutgers Offers Hope in New Treatment for Spinal Cord Injuries
3/18/2011
In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months
10/20/2010
Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
8/18/2010
Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
7/15/2010
Nitto Denko and Quark Pharmaceuticals to Enter into Collaboration to Develop a Novel siRNA Anti-fibrotic Drug
6/28/2010
Quark Pharmaceutical’s QPI-1007 Exhibits Neuroprotective Effects in Glaucoma Model
6/24/2010
Quark Pharmaceuticals Announces Presentations of its Two siRNA Drug Candidates at Glaucoma & Retinopathies 2010
6/15/2010
Quark Granted European Orphan Drug Status for QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients
6/10/2010
Quark Pharmaceuticals Closes $10 Million Financing
SBI Holdings, Inc. CEO Yoshitaka Kitao Appointed to Board. Funds to Support Advancing Clinical Pipeline.
5/17/2010
Quark Pharmaceuticals Announces Nature Medicine Publication for Role of RTP801 in Pulmonary Injury and Emphysema
5/6/2010
Quark Pharmaceuticals Development Partner Pfizer Presents In Vivo Activity of PF-04523655 at ARVO
5/4/2010
Quark to Present Data on Predicting Risk of Delayed Graft Function in Kidney Transplant Patients at American Transplant Congress
5/4/2010
Quark to Present Phase I Data for QPI-1002 in DGF
3/1/2010
Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
2/16/2010
FDA Grants Orphan Drug Status for Quark’s QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients
12/6/2009
Quark Pharmaceuticals Poised to Advance Clinical Studies of QPI-1002
First Synthetic siRNA Administered Systemically to Humans for the Prophylaxis of Acute Kidney Injury and Delayed Graft Function
11/19/2009
Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
11/2/2009
Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
10/26/2009
Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
8/4/2009
Quark Pharmaceuticals to Participate in IBC’s Oligonucleotide Therapeutics: From Concept to Implementation Conference
7/28/2009
Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
6/9/2009
Quark Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
5/14/2009
Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
5/11/2009
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
4/20/2009
Quark Pharmaceuticals Presents at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
3/9/2009
Quark Pharmaceuticals Presents at Asia TIDES Conference
Highlights First Systemic siRNA Administered in Humans and Quark’s Proprietary siRNA Structures
1/8/2009
Quark Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Kidney transplantation to be Quark’s second indication with clinical-stage, systemically administered siRNA product candidate for Delayed Graft Function
12/1/2008
Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
Presentation to Highlight Results of Ocular Neuroprotection Candidate
10/13/2008
Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Quark siRNAs Examined Alone and in Combination with Chemotherapy
9/25/2008
Quark Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Data Validates Neuroprotective Effect of Quark’s New RNAi product on dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma
9/17/2008
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
7/30/2008
Quark Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in DME
Clinical Program Leverages Quark’s RNAi Technology
4/7/2008
Quark Receives FDA Approval of IND For Kidney Transplant
Quark’s second siRNA drug delivered systemically
4/7/2008
Quark Closes $27 Million Financing
Funds Will Support Clinical Development of Pipeline Products
12/23/2007
Quark to Present at JPMorgan 26th Annual Healthcare Conference
Quark Pharmaceuticals to Present New Preclinical Proof of Concept Results at JPMorgan 26th Annual Healthcare Conference
11/19/2007
Quark Announces First Systemic siRNA Dosing
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans. Commences Phase I Clinical Trial of Proprietary siRNA Molecule in Acute Renal Failure.
10/23/2007
Quark to Present at CIBC and Acumen BioFin Rodman & Renshaw
Quark Pharmaceuticals to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10/10/2007
Development Milestone Payment from Mitsubishi
Quark Pharmaceuticals, Inc. to Receive Development Milestone Payment from Mitsubishi Pharma Corporation
9/25/2007
Development of Proprietary siRNA Compounds for Noise-Induced Hearing Loss
Quark Pharmaceuticals Signs Collaboration Agreement with University of Michigan for Development of Proprietary siRNA Compounds for Noise-Induced Hearing Loss
8/28/2007
Patent Application on RNAi molecules
Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications To Its RNAi Molecules
8/21/2007
Agreement with University of NY
Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
8/6/2007
Positive Preclinical Results
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Quark to initiate Phase 1 trial of AKIi-5 as the first human clinical study involving the systemic delivery of siRNA
7/31/2007
Silence Therapeutics and Quark
Silence Therapeutics plc and Quark Pharmaceuticals, Inc. (“Quark”), announced today an expansion of their current strategic technology licensing agreement
9/26/2006
Pfizer and Quark
Pfizer expands research commitment to ophthalmology through licensing agreement with quark biotech...
6/19/2005
COPD
Quark Biotech Discovers Role of RTP801 as Signaling Molecule in Cigarette Smoking-Induced Pulmonary Injury...